Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/1b study of ASP2074 in advanced solid tumors
jRCT2031220554Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of ASP2074 in Non-hematologic malignancy, colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC) and 3 more (2 arms), sponsored by Astellas Pharma. Primary endpoints: Dose-limiting toxicities, Adverse events and 4 more. Started Feb 2023; status: completed.
02
Drugs
ASP2074
03
Conditions
Non-hematologic malignancycolorectal adenocarcinomapancreatic adenocarcinoma (PDAC)gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031220554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220554.